Jonathan Piccini
Cardiovascular Disease · Durham, NCNPI 1003884693
Payments from drug & device makers
Across 854 payments — averaging $16,800 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$11.4M
- Boston Scientific$761K
- Irhythm Technologies, Inc.$723K
- Abbott$589K
- Medtronic$352K
- Philips North America LLC$310K
- plus $201K from 19 others
Across 47 payments — averaging $8049.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$254K
- Philips North America LLC$116K
- Boston Scientific$4K
- Sanofi-aventis U.S. LLC$3K
- AbbVie$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 38 | $11,410,758 |
| Boston Scientific | 153 | $761,276 |
| Irhythm Technologies, Inc. | 15 | $723,318 |
| Abbott | 171 | $589,335 |
| Medtronic(2 entities) | 299 | $351,942 |
| Philips North America LLC | 63 | $309,703 |
| Recor Medical Inc | 1 | $69,000 |
| Biotronik Inc. | 13 | $26,776 |
| AbbVie(2 entities) | 26 | $23,934 |
| Biosense Webster, Inc. | 2 | $20,118 |
| Gilead | 2 | $19,996 |
| E.r. Squibb & Sons, L.L.C. | 5 | $15,680 |
| Livanova USA, Inc. | 38 | $11,000 |
| Pfizer | 3 | $4,200 |
| Novartis | 2 | $2,815 |
| Bayer | 10 | $2,148 |
| Eli Lilly | 2 | $1,800 |
| Pacira Pharmaceuticals Incorporated | 1 | $1,640 |
| Altathera Pharmaceuticals LLC | 1 | $1,000 |
| Janssen Research & Development, LLC | 3 | $297 |
| Volta Medical Inc | 2 | $236 |
| Cortex, Inc. | 1 | $172 |
| Acutus Medical, Inc. | 1 | $98 |
| LSI Solutions Inc | 1 | $83 |
| Atricure, Inc. | 1 | $32 |
How this compares
$14,347,358 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Durham
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
- Nishant ShahDurham$3.5M
- Andrew AmbrosyDurham$3.2M
- Michel KhouriDurham$2.4M
- R WilliamsDurham$2.1M
- Andrew WangDurham$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.